SARS-CoV-2

Dr Nevan Krogan, Founder of the UC San Francisco (UCSF) Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG) and Director of QBI, has been awarded France’s Legion of Honor.  The award was given for forming an international research collaboration and for scientific contributions utilising a novel methodology of identifying the viral modifications of human proteins […]

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses.  A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2 virus from entering cells and causing respiratory disease.  “Rather […]

A new App Note is now available, sponsored by Analytik Jena: Rapid Development of Automated Sars-CoV-2 Clinical Diagnostics. Download to learn about: How to create and share an automated workflow for rapid development and validation of SARS-CoV-2 clinical diagnostics. The highly scalable liquid handling platform, CyBio FeliX for clinical diagnostics – it provides magnetic bead-based nucleic […]

Download the App Note to learn about: How to create and share an automated workflow for rapid development and validation of SARS-CoV-2 clinical diagnostics. The highly scalable liquid handling platform, CyBio FeliX for clinical diagnostics – it provides magnetic bead-based nucleic acid extraction, eliminating laborious and time-consuming column-based binding and spinning steps. Automating your diagnostic […]

The amount of SARS-CoV-2 antibodies in the blood of patients hospitalised with Covid-19 could be used to predict illness severity and other clinical outcomes.  A new study, published in the Annals of Internal Medicine, shows that higher levels of viral antigen in the blood, which could indicate ongoing SARS-CoV-2 replication, correlated with more severe disease.  The […]

Listen to this article on the DDW Podcast: An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools and technologies, and that fast-paced innovation gives […]

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles in terms of activity and […]

Scientists at the Institut Laue-Langevin (ILL), in collaboration with the Paul Scherrer Institut (PSI), the Institut de Biologie Structurale (IBS) and the Australian Nuclear Science and Technology Organisation (ANSTO), have published new data on how the SARS-CoV-2 spike protein interacts with mammalian lung cell membranes, allowing the viral RNA to enter human cells.  The purpose […]

We know there are operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is slow and expensive, with high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the current pandemic is prompting a fundamental reassessment of strategic priorities. […]

The Covid-19 pandemic has promoted global efforts to develop antiviral treatments against SARS-CoV-2. During this process, the endemic operational vulnerabilities of the drug discovery process have been highlighted. The reality is: bringing new drugs to the market is associated with high costs, high failure rates and long cycle times…and this process is becoming slower and […]